First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and pred...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2019-04, Vol.37 (12), p.984-991
Hauptverfasser:	Flinn, Ian W, van der Jagt, Richard, Kahl, Brad, Wood, Peter, Hawkins, Tim, MacDonald, David, Simpson, David, Kolibaba, Kathryn, Issa, Samar, Chang, Julie, Trotman, Judith, Hallman, Doreen, Chen, Ling, Burke, John M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Hydrochloride - administration & dosage Cyclophosphamide - administration & dosage Doxorubicin - administration & dosage Humans Lymphoma, Mantle-Cell - drug therapy Lymphoma, Non-Hodgkin - drug therapy ORIGINAL REPORTS Prednisone - administration & dosage Progression-Free Survival Proportional Hazards Models Rituximab - administration & dosage Survival Rate Vincristine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!